Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Podcast 38: CDMOs/CMOs Expand High-Potency API Manufacturing

Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments.

Key topics: (see Chapter Markers in drop down menu in audio player above)

  • A roundup of recent investments in HPAPI manufacturing (1:14)
  • WuXi STA (1:31)
  • MilliporeSigma (2:28)
  • Piramal Pharma Solutions (3:25)
  • Cambrex (5:26)
  • HAS Healthcare Advanced Synthesis (7:07)
  • AGC Fine Chemicals (8:30)
  • Lonza (9:11)
  • Carbogen Amcis (11:44)
  • Sterling Pharma Solutions (12:14)
  • Ajinomoto Bio-Pharma Services (13:22)
  • Novasep (14:02)
  • Olon (14:47)
  • Cerbios-Pharma (16:36)
  • Formosa Laboratories (17:44)
  • Sai Life Sciences (18:31)
  • BSP Pharmaceuticals (19:15)
  • Seqens (20:01)
  • CordenPharma (20:14)

Sponsor: BIOVECTRA

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show 

You May Also Like

Podcast 44: What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights…

Podcast 43: CDMOs/CMOs: The Movers and Shakers of 2023

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the…

Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an…

Podcast 41: API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains 

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages…